title: Failure to reproduce the in vitro cardiac electrophysiological effects of naloxone in humans.
abstract: 1. Opioid receptor antagonists such as naloxone have shown antiarrhythmic activity in animal models of coronary artery occlusion. Studies have indicated that these effects are stereospecific but both isomers of naloxone prolong action potential duration and refractoriness in guinea-pig and rabbit isolated ventricular myocardium (Class III effect). 2. This study was performed to identify whether this Class III effect of naloxone could be reproduced in human myocardium in vivo. Twenty patients with coronary artery disease received intravenous racemic naloxone (1-40 micrograms kg-1 min-1). Surface electrocardiographic parameters were measured and refractory periods were determined during fixed rate pacing by programmed stimulation. 3. The corrected QT interval during sinus rhythm (SR-QTc) was prolonged by 5(3)% (P = 0.06) at a dose of 20 micrograms kg-1 min-1 and by 9(10)% at 40 micrograms kg-1 min-1 (P = 0.03). These small changes were lost at higher paced heart rates. No significant effects on atrial, atrioventricular nodal or ventricular refractoriness were seen. 4. Plasma naloxone concentrations well into the micromolar range were achieved with both of the higher doses of naloxone administered. Plasma beta-endorphin concentrations invariably increased following naloxone infusion. There was no statistical relationship between peak plasma naloxone concentrations and the absolute or percent prolongation of SR-QTc. 5. It seems unlikely that racemic naloxone would have any clinical utility as an antiarrhythmic agent. Racemic naloxone may enhance cardiac adrenergic nerve activity and this receptor mediated effect may have prevented the demonstration of any nonreceptor mediated prolongation of cardiac refractoriness. Studies with the individual stereoisomers of naloxone would be of interest.
authors.affiliation: Department of Medical Cardiology, Royal Infirmary, Glasgow, UK.
authors.forename: K G
authors.initials: KG
authors.lastname: Oldroyd
authors.forename: A C
authors.initials: AC
authors.lastname: Rankin
authors.forename: C E
authors.initials: CE
authors.lastname: Gray
authors.forename: K
authors.initials: K
authors.lastname: Harvey
authors.forename: W
authors.initials: W
authors.lastname: Borland
authors.forename: A P
authors.initials: AP
authors.lastname: Rae
authors.forename: S M
authors.initials: SM
authors.lastname: Cobbe
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D003327:Coronary Disease / Q000503:physiopathology*; D004562:Electrocardiography / Q000187:drug effects*; D004594:Electrophysiology; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009270:Naloxone / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D011863:Radioimmunoassay; D013237:Stereoisomerism; D001615:beta-Endorphin / Q000097:blood*
chemical_list: D009270:Naloxone; D001615:beta-Endorphin